Loading…
Loading…
The Goldman Sachs Future Health Care Equity ETF (the “Fund”) seeks long-term growth of capital. The fund invests in innovators and disruptors in the healthcare sector by looking for companies that are developing new treatments and technologies, primarily in genomics, precision medicine, tech-enabled procedures, and digital healthcare.
Is GDOC's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.
GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.
Biotech investing may not be the most obvious place for investors to look right now, but factors may be turning in the category's favor. Multiple rate cuts in the back half of 2025 and a friendlier regulatory regime may position biotech investing as a shrewd option to end the year.
Is now the time to consider biotech ETFs? The stars may be aligning for investing in biotech as 2025 draws to a closer, with ETFs a key route into the space.
Active management in ETFs are gaining market share in 2023, as leading managers bring their best ideas into the ETF industry. As of July 31, 169 active ETFs had launched in 2023, comprising nearly 70% of total ETF launches.